ArticleSubstance use : research and treatment
Alcohol Consumption Impacts Liver Fibrosis Progression in Minority of Patients Screened for Hepatitis C at Drug Treatment Centers.
Article in Substance use : research and treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Hepatitis C virus (HCV) infection is a prevalent disease at drug treatment centers (DTC). Alcohol abuse may also contribute to liver fibrosis at DTC, which may affect the prescription of HCV therapy. This study evaluated the risk of alcohol intake and other predictive factors for fibrosis progression. Methods: An on-site dried-blood-spot (DBS) testing program for hepatitis C care at DTC from 2017 to 2019 was used to identify patients with previous HCV-antibody testing and fibrosis score data. Patients were grouped based on RNA status, alcohol intake and advanced liver disease (ALD ⩾ F3). Fibrosis progression was assessed using APRI and FIB-4. Kaplan-Meier and Cox-regression analyses were performed. Results: Positive HCV RNA patients (n = 138) exhibited a higher rate of ALD (11% vs 2.2%, Conclusions: Patients with active HCV infections at DTC have an increased risk for ALD compared to patients without HCV. High-risk alcohol consumption is present in a minority of patients aggravating fibrosis. These results suggest that HCV treatment should not be delayed at DTC regardless of alcohol consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.